SCHEMBL6964590

SCHEMBL6964590

O=C(CCCl)Oc1ccccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
PTK2B Q14289 1/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
PKM P14618 1/20 0.44
CXCL8 P10145 1/20 0.44
BCHE P06276 1/20 0.43
RECQL P46063 2/20 0.41
HPGD P15428 1/20 0.41
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TP53 P04637 1/20 0.41
HTT P42858 1/20 0.41
MAPT P10636 2/20 0.41
POLB P06746 3/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7880255 0.93 ALDH1A1 (0.41) ALDH1A1PTK2BMEN1KMT2APKM
SCHEMBL8496813 0.90 PTK2B (0.47) ALDH1A1PTK2BMEN1KMT2APKM
SCHEMBL8498810 0.87 KMT2A (0.50) ALDH1A1PTK2BMEN1KMT2APKM
SCHEMBL13505905 0.87 MEN1 (0.50) ALDH1A1PTK2BMEN1KMT2APKM
SCHEMBL7049564 0.85 MEN1 (0.49) ALDH1A1PTK2BMEN1KMT2APKM
SCHEMBL8496997 0.85 MEN1 (0.49) ALDH1A1PTK2BMEN1KMT2APKM
SCHEMBL28189795 0.85 MEN1 (0.50) PTK2BMEN1KMT2APKMCXCL8
SCHEMBL6917578 0.84 ALDH1A1 (0.54) ALDH1A1PTK2BMEN1KMT2APKM
SCHEMBL27810380 0.84 PTK2B (0.43) ALDH1A1PTK2BMEN1KMT2APKM
SCHEMBL4644269 0.81 GAA (0.47) ALDH1A1MEN1KMT2ARECQLHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0863136-B1 Derivatives of azetidine and pyrrolidine AKZO NOBEL NV (NL) 2003-09-24 EP disclosed
US-6403573-B1 BICYCLIC-CARBO OR HETERO OXY OR BICYCLIC CARBO OR HETERO SULFIDE CONTAINING PYRROLIDINE/AZETIDINE DERIVATIVES USED AS ANTIDEPRESSANT OR PREVENTING SEROTONIN-RELATED DISEASES AKZO NOBEL N.V. (NL) 2002-06-11 US disclosed
US-20020040016-A1 Derivatives of azetidine and pyrrolidine MERCK SHARP & DOHME B.V. (NL) 2002-04-04 US disclosed
US-6281243-B1 ANTIDEPRESSANTS, ANTISEROTONINE AGENT AKZO NOBEL N.V. (NL) 2001-08-28 US disclosed
WO-1999043647-A1 DERIVATIVES OF AZETIDINE AND PYRROLIDINE AKZO NOBEL N.V. (NL) 1999-09-02 WO disclosed
EP-0863136-A1 Derivatives of azetidine and pyrrolidine Akzo Nobel N.V. (NL) 1998-09-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040016-A1 Derivatives of azetidine and pyrrolidine TPH1, TPH2, HTR1D ALDH1A1 298/4885PTK2B 3224/4885MEN1 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.